TIGER
A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel followed by High-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumours
III
interventionell
International
Cisplatin, Ifosfamid, Paclitaxel, Carboplatin, Etoposid
Status: In Rekrutierung
Zeitraum
2016
2022
Zentren
11
11
Keine Zentren gesucht
Patienten
75
59
19.04.2022
Klinische Settings
2nd line
palliativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Alliance for Clinical Trials in Oncology
Kooperierende Fachgesellschaft(en)
National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer - EORTC Movember Foundation Institute of Cancer Research (ICR), United Kingdom Cancer Research UK UNICANCER Irish Group CTI
Förderer
Deutsche Krebshilfe
Identifier
AIO-GC-0416/ass
AIO-GC-0416/ass
A031102,U10CA180821 (U.S. NIH Grant/Contract),NCI-2014-01696 (Registry Identifier: NCI Clinical Trial Reporting Program)
Kontakt
Leitung
Prof. Dr. med. Marcus Hentrich
Ansprechpartner*in
Susanne Harnisch / Kerstin Balthasar
E-Mail susanne.harnisch@kks.uni-marburg.de